Company news

Capricor Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

March 1, 2022

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

January 24, 2022

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

December 12, 2021

Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 8, 2021

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

September 23, 2021

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021

September 1, 2021

Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 11, 2021

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

August 3, 2021

Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors

July 26, 2021

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 12, 2021

Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio

April 28, 2021

Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

March 10, 2021

Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform

March 8, 2021

Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11

March 3, 2021

Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

January 31, 2021

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

January 18, 2021

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

January 11, 2021

Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients

December 28, 2020

Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19

November 23, 2020

Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 11, 2020

Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19

November 8, 2020

Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020

September 22, 2020

Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19

August 24, 2020

Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 5, 2020

Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 13, 2020

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002

May 12, 2020

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy

April 2, 2020

Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 17, 2020

Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion

March 16, 2020

Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

December 18, 2019

Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market

December 16, 2019

Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update

November 6, 2019

Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

October 6, 2019

Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5: 30 AM PT / 8: 30 AM ET

October 1, 2019

Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

September 23, 2019

Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

September 16, 2019

← Newer news releases

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 38 decks. Every deck is listed under its year.